Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal Cancer.
Eric Van CutsemRona YaegerJean-Pierre DelordJosep TaberneroLillian L SiuMichel DucreuxSalvatore SienaElena Elez FernandezStefan KasperThomas ZanderNeeltje SteeghsDanielle MurphyMichelle EdwardsZev A WainbergPublished in: The oncologist (2023)
The combination of binimetinib and panitumumab had substantial toxicity and limited clinical activity for patients with mutant or WT RAS mCRC, independent of EGFRi treatment history (Trial registration: NCT01927341).